Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)’s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.72 and traded as low as $1.36. Eagle Pharmaceuticals shares last traded at $1.50, with a volume of 1,234 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Eagle Pharmaceuticals in a research note on Tuesday. They issued a “hold” rating for the company.

Eagle Pharmaceuticals Trading Up 0.7 %

The company has a 50 day simple moving average of $0.79 and a 200 day simple moving average of $1.72.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several large investors have recently bought and sold shares of the company. DGS Capital Management LLC increased its stake in Eagle Pharmaceuticals by 44.9% during the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 22,239 shares in the last quarter. Jane Street Group LLC purchased a new stake in Eagle Pharmaceuticals during the 3rd quarter worth approximately $96,000. RBF Capital LLC increased its stake in Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 14,991 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Eagle Pharmaceuticals during the 3rd quarter worth approximately $453,000. Finally, Creative Planning acquired a new position in shares of Eagle Pharmaceuticals during the 3rd quarter worth approximately $59,000. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.